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Abstract
Objective—Medicare Part D claims are commonly used for research, but missing claims could 
compromise their validity. This study assessed two possible causes of missing claims: veteran 
status and Generic Drug Discount Programs (GDDP).
Methods—We merged medication self-reports from telephone interviews in the Atherosclerosis 
Risk in Communities Study (ARIC) with Part D claims for six medications (three were commonly 
in GDDP in 2009). Merged records (4,468) were available for 2,905 ARIC participants enrolled in 
Part D. Multinomial logit regression provided estimates of the association of concordance (self-
report & Part D, self-report only, or Part D only) with veteran and GDDP status, controlling for 
participant socio-demographics.
Results—Sample participants were 74±5 years of age, 68% white and 63% female; 19% were 
male veterans. Compared to females, male veterans were 11% (95% CI: 7%–16%) less likely to 
have matched medications in self-report & Part D and 11% (95% CI: 7%–16%) more likely to 
have self-report only. Records for GDDP versus non-GDDP medications were 4% (95% CI: 1%–
7%) more likely to be in self-report & Part D and 3% (95% CI: 1%–5%) less likely to be in Part D 
only, with no difference in self-report only.
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Conclusions—Part D claims were more likely to be missing for veterans, but claims for 
medications commonly available through GDDP were more likely to match with self-reports. 
While researchers should be aware of the possibility of missing claims, GDDP status was 
associated with a higher rather than lower likelihood of claims being complete in 2009.
INTRODUCTION
Prescription claims data are increasingly used by various organizations including pharmacy 
benefit managers, insurers, pay-for-performance contractors and researchers.1 The Centers 
for Medicare & Medicaid Services (CMS) adopted adherence quality measures, developed 
by the Pharmacy Quality Alliance, which measure patients’ adherence to long-term therapy 
with pharmacy claims.2 Medicare Part D sponsors receive financial incentives contingent on 
a star rating system.2 CMS star ratings include Core Measures that focus on prescribing 
selected medications for specific diseases.
Prescription claims undergo numerous audit and validity checks during the filing and billing 
processes to ensure accuracy.3 Despite the growing interest in using prescription medication 
claims for research and quality monitoring purposes, the completeness of Medicare Part D 
claims has yet to be fully investigated. Discrepancies between self-reported medication use 
and Part D claims may be due to different reasons: recall bias, free samples from providers, 
and provision or purchase from another source (e.g., the Veteran’s Administration Pharmacy 
Benefit, Generic Drug Discount Programs (GDDP), State Pharmaceutical Assistance 
Programs, out-of-pocket purchase, or mail order from foreign countries).4 Conversely, Part 
D claims may be found for drugs not reported by an individual for reasons including recall 
bias or filled prescriptions that are subsequently not taken.
While we are not aware of a data source that would allow a comprehensive assessment of 
the role of all causes of incomplete claims data, this study assesses the extent of two 
important potential deficiencies in Medicare Part D claims: veteran status and GDDP 
coverage. Although not all veterans are covered by the VA Pharmacy Benefit, some veterans 
may fill prescriptions through the VA Pharmacy Benefit even when they are enrolled in 
Medicare Part D, especially since the VA Pharmacy Benefit is considered more generous 
than Medicare Part D.5 The rapid increase in the offering of GDDPs, often referred to as “$4 
generics,” by major pharmaceutical chains over the last decade may lead to under-
representation of total medication consumption by Part D claims. Pharmacies are 
encouraged to submit GDDP claims to the Medicare program, but such submission is not 
required, and pharmacies generally do not receive additional reimbursement for submission. 
We first review issues and existing evidence about claims completeness. We then assess 
trends in claims submission using Medicare Part D claims from 2006–2009 for participants 
in the Atherosclerosis Risk in Communities Study (ARIC).6 The claims were merged with 
self-reported medications in 2009 to assess concordance between claims and self-reports. 
Concordance was assessed overall and using multinomial logit regression to identify the 
association of the two variables of interest with missing Part D claims.
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Claims Completeness: Concerns and Prior Evidence
Since veterans may receive their medications through the VA Pharmacy Benefit, analyses of 
Part D claims have sometimes simply excluded veterans when veteran status was known,7 
while medication adherence studies for veterans often use VA data.8 The completeness of 
prescription claims became a further concern for analysts over the last decade, due to the 
implementation of GDDPs by major retail chain pharmacies.9 The programs permit patients 
to purchase generic medications on a select list for a low out-of-pocket price (e.g., $4–$10 
per month or $10–$12 for a 3-month supply). A 2011 survey of members of a university-
affiliated health system found the use of GDDPs by its members increased from 5% to 32% 
between 2008 and 2010.10
Some researchers have expressed concerns that pharmacies may not submit prescription 
claims to the pharmacy benefit manager if a patient uses a GDDP and pays out-of-pocket.1 
Gaps in claims data could substantially impact the validity of studies utilizing claims for 
various purposes.11, 12 However, Medicare beneficiaries may present their Medicare ID and 
Part D plan information even when paying cash to buy generic medications, and Part D 
plans often adjudicate the $4 claims to track total medication purchases.13 One study using 
the 2007 Medicare Current Beneficiary Survey (MCBS) found 97% of $4 medications on 
the GDDP list for a major pharmacy that were purchased out-of-pocket were adjudicated 
through Medicare Part D.9 This high rate may occur because pharmacies may have a 
customer’s Medicare information on file for other medication purchases and automatically 
file claims even if a GDDP covered the payment in full. In 2012, CMS issued a memo 
reinforcing its recommendation that Medicare Part D sponsors should encourage network 
pharmacies to submit all claims for medications provided to Part D beneficiaries.14
Several prior studies assessed the impact of GDDPs on the completeness of non-Medicare 
prescription claims; the results were conflicting but showed evidence of the potential for 
missing claims.4, 15, 16 Based on Medical Expenditure Panel Survey (MEPS) self-reports of 
medication fills/ expenditures merged with Part D claims, researchers concluded that people 
tended to over-report the number of fills per medication (possibly due to reporting free 
samples from providers) but to underreport the number of medications.17 However, the data 
were from 2006–2007, which was at the start of the expansion of GDDP plans, and the study 
excluded veterans since federal pharmacies (including VA pharmacies) do not file Part D 
claims. Other investigators found a high rate of Part D fills for MEPS respondents in 2007, 
though their conclusions were contested with anecdotal reports that smaller pharmacies are 
substantially less likely to file Part D claims.18, 19 A recent assessment using the 2009 
MCBS found little evidence of out-of-plan use of discounted generics that was not 
adjudicated by Medicare and also showed that prescriptions filled at VA pharmacies or other 
sources only accounted for about 1% of total prescription fills.20 However, this study did not 
assess the association of veteran or GDDP status jointly with concordance while controlling 
for other enrollee characteristics.
In total, prior analyses do not provide a comprehensive assessment of the association of 
veteran status or GDDP coverage with Medicare Part D claims completeness. We therefore 
use Medicare claims data merged with medication self-reports to assess the extent of 
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possible deficiencies in Part D claims for participants in community surveys such as ARIC 
from these two causes.
METHODS
Study Population
The Atherosclerosis Risk in Communities (ARIC) Study is an ongoing prospective 
population-based cohort study comprised of 15,792 adults aged 45–64 years at recruitment 
in 1987–1989.6 Cohort participants were selected from four US communities: Forsyth 
County, NC; Jackson, MS; Minneapolis, MN; and Washington County, MD. Participants 
completed five clinical exams between 1987 and 2013 and were contacted for annual 
follow-up telephone interviews. Ancillary to ARIC, 91% of the surviving cohort also 
participated in the Life Course Socioeconomic Status, Social Context and Cardiovascular 
Disease Study, which asked about veteran status.21 ARIC cohort participants were linked 
with CMS Medicare Part D claims from 2006–2009 for the Part D drug benefit that started 
in 2006.
During annual telephone interviews conducted by ARIC, the interviewer queried 
respondents about the names of all the medications used in the past two weeks. Merged Part 
D claims include the nonproprietary and proprietary names, date filled, and days supplied 
for each medication dispensed.
Medications Selected for Analysis
Six medications were selected based on high interview self-reporting frequency and likely 
inclusion versus non-inclusion on GDDP plan drug lists in 2009. To confirm broad use of 
the medications selected, we utilized web-based historical information to identify 
medications consistently found on GDDP lists in 2009 for 5 major pharmaceutical 
companies (Walmart, CVS, Walgreens, Target, and K-Mart); we also reviewed the 
medication lists and selected medications with two pharmacists. Table 1 lists the generic and 
brand names, drug class, and typical indications for the medications. The non-GDDP 
medications were primarily brand-name medications (except for amlodipine which was 
released as generic in 2007) that were not on the GDDP lists in these major pharmacies in 
2009.
Linkage for Assessing Medication Self-Report and Claims Concordance
Figure 1 shows the steps in merging the medication self-reports and Part D claims. The 2009 
telephone interview was administered to 11,599 ARIC participants. We excluded 1,480 
people who refused to report medications used and 4,596 people who were enrolled in Part 
D for less than four months prior to the interview date (as Part D prescriptions are often 
filled for 90 days). Keeping only medication reports in the six selected medication 
categories resulted in 4,149 medication reports for 2,632 people.
For Part D claims, we identified 65,712 Part D claims for 4,232 ARIC participants in 2008–
2009 in the six medication categories. We then limited the sample to claims which were 
filled before the interview (with days supplied overlapping the interview date) or up to 30 
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days afterwards to allow for overstock due to refills or moderate adherence. This step 
resulted in 3,875 claims for 2,806 people.
Finally, we merged interview medication self-reports and Part D claims by medication name 
and classified records from the merge into one of three categories: in both self-report and 
Part D, only in self-report, or only in Part D. We excluded an additional 127 people who 
were missing veteran status. The final analysis file had 4,468 merged records for 2,905 
people.
Analyses and Statistical Methods
We conducted three analyses to describe and assess the completeness of Medicare Part D 
claims. The first analysis used Part D claims from 2006–2009 to characterize the rate over 
time at which participants’ out-of-pocket payments constituted the full payment for the 
medication, which could reflect GDDP filings. Since prescriptions may be filled for varying 
amounts of time (e.g., 30 days, 90 days, etc.), we adjusted the measures in this analysis to 
reflect 30 day prescriptions. The second analysis used the merged Part D claims and 
interview self-reports in 2009 to calculate medication concordance statistics (overall and by 
GDDP status). The Kappa statistic provides an assessment of concordance (i.e., agreement 
from two different sources of information), with values as follows: poor (<0.20), fair (0.20–
0.40), moderate (0.41–0.60), good (0.61–0.80), and very good (0.81–1.00).22, 23 The third 
analysis provided tests of two specific hypotheses:
H1: Relative to non-veteran males and females, male veterans are less likely to have 
matched claims and more likely to have medication reports that are self-report only.
H2: Medications typically on GDDP plans in 2009 are less likely to have matched 
claims and more likely to have medication reports that are self-report only.
The first hypothesis is based on the fact that veterans may obtain medications from the VA 
Pharmacy Benefit rather than through Part D. The second hypothesis will be supported if 
claims are less likely to be submitted to Part D when the patient’s payment for a GDDP plan 
is the total payment (e.g., for a $4 generic).
Multinomial logit regression was used to test these hypotheses by examining whether the 
likelihood of the trichotomous measure of concordance (in both, self-report only, or Part D 
only) differed in 2009 for veterans or for medications on the GDDP lists versus not on the 
GDDP lists. Covariates included in the regression were: age, gender, and ARIC site 
interacted with race. (The small number of study participants who were not white or black 
were excluded from the analysis.) All included ARIC participants in Jackson, MS are black, 
while all included participants in Minneapolis, MN and Washington County, MD are white. 
Forsyth, NC is the only site with variation in race. Only two females in the ARIC sample 
were identified as veterans; therefore, female veterans were grouped with female non-
veterans and included in the referent group. The regression model is subject to the 
“Independence of Irrelevant Alternatives (IIA) assumption” which was tested using a 
Hausman test, with no evidence of violation of IIA assumption. We adjusted the standard 
errors for clustering on individuals, since many individuals had multiple medication reports 
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in the file.24 Statistical tests of a model using a quadratic form for age showed that age had a 
linear rather than non-linear relationship with concordance.
The main regression model investigated the effect of veteran and GDDP status while 
controlling for study participant age, race and geographic location. Marginal effects for each 
variable, standard errors for the estimated marginal effects, and 95% confidence intervals 
were generated using the method of recycled prediction for categorical variables and the 
calculus method for the continuous variable age. To investigate the consistency of specific 
medication effects, we estimated two additional models using: (1) separate indicators for 
each GDDP medication (with overall non-GDDP status as the referent group); and (2) 
separate indicators for the non-GDDP medications (with overall GDDP status as the referent 
group).
The regressions control for key person or programmatic factors that may be associated with 
concordance between claims and self-report. Several important pieces of information were 
not available from either source, including: whether the individual actually purchased the 
medication through a GDDP plan, whether the person was using the Veteran pharmacy 
benefit, and whether the person had some other source of payment for medications (e.g., 
State pharmacy assistance benefit program). While these gaps in information limited 
definitive determination of sources of non-concordance, the identification of key factors 
associated with non-concordance is still instructive to researchers using claims or self-
reports of medications.
RESULTS
Trends in Part D Claims Payments Over Time
The last four columns of Table 1 provide trends for Part D claims from 2006–2009 for the 
six medications. Compared to non-GDDP medications, a relatively high proportion of 
claims for the GDDP medications had patient pay amounts that equaled total payment for 
the medication, as might occur for medications obtained through GDDP plans (though we 
cannot rule out simple “payment in full” for the drugs under Part D). In contrast, the non-
GDDP medications had a much lower rate of claims where the patient pay amount equaled 
the total payment amount. (For both categories, some claims may have been for higher 
payments while the beneficiary was in the Part D “donut hole” where the beneficiary is 
responsible for the full medication payment.) The percent of claims where gross drug 
payment equaled patient pay amount increased over time for the GDDP medications. 
whereas it decreased over time for the non-GDDP medications. Patient out-of-pocket 
payments (adjusted to reflect 30 day prescriptions) for the GDDP medications were 
relatively low and declined from 2006 to 2009. In contrast, the out-of-pocket payments were 
much higher and increased over time for the non-GDDP brand name medications.
Concordance Statistics between Part D Claims and Self-reports
Table 2 provides statistics on the concordance by GDDP status for the 4,468 medication 
reports for the 2,905 ARIC participants with self-reports and/or Part D claims for the 
selected medications in 2009. The first column of Table 3 provides descriptive statistics for 
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the sample; the mean age was 74±5.4 years, 63% were female, and 68% were white. Almost 
20% of participants were male veterans.
Interestingly, GPPD medications had a higher rate of concordance (i.e., being in both the 
self-reports and Part D claims) of 77.0% than non-GPPD drugs (72.4%), indicating good 
agreement. Overall, the GDDP medications (k=0.85) had higher concordance than non-
GDDP medications (k=0.78). The specific medications all had kappa statistics indicating 
good to very good concordance.
Regression Analysis
The regression coefficients for the main model in Table 3 provide estimates of the 
association between concordance and the two characteristics that are hypothesized to be 
associated with lower concordance (male veteran status and GDDP drug), while controlling 
for participant characteristics. Interpretation of the association is facilitated by the marginal 
effects. Figure 2 provides predicted values of the three concordance categories for male 
veteran status and GDDP medication status and the corresponding marginal effect from 
Table 3. Figure 2a shows that relative to females, male veterans were 11.1% (95% CI: 
6.8%–15.5%) less likely in both the self-report & Part D and were 11.3% (95% CI: 7.2%–
15.5%) more likely in self-report only. The probability of being Part D only did not vary 
significantly for male veterans versus females. Male non-veterans did not differ significantly 
from females for any of the three concordance categories, and the 95% confidence intervals 
for the marginal effects for male non-vets and male vets did not overlap. Therefore, the 
hypothesis that male veterans would be more likely to have a lower match rate and a greater 
rate of self-reports than females or male non-veterans is supported.
Figure 2b, however, does not support the second hypothesis that Part D claims would be 
more likely to be missing for GDDP medications. Compared to non-GDDP medications, 
GDDP medications were 3.9% (95% CI: 1.4%–6.5%) more likely to be in both self-report 
and Part D and were not significantly more likely to be in self-report only. The higher match 
rate for GDDP medications is also reflected by the fact that GDDP medications were 2.8% 
(95% CI: 1.1%–4.6%) less likely to be in Part D only.
Other regression coefficients and estimated marginal effects in Table 3 show that 
concordance varied significantly by geographic site and, to some extent, race. As noted 
earlier, it is not possible to fully disentangle race and site effects in the ARIC sample 
because the Minneapolis, MN and Washington County, MD sites consist only of whites, 
while the Jackson site has only blacks. This site/race variation in concordance could be due 
to claim filing policies of individual pharmacies in the areas.
The regressions examining specific medications show consistent patterns for the likelihood 
of being in both the self-report and Part D claims for the three separate GDDP medications 
versus the combined group of non-GDDP medications. The regression results are available 
on request; Appendix Figures A1 and A2 show the marginal effects. Only lisinopril had a 
statistically significantly higher likelihood of being in both self-report and Part D as well as 
Part D only. Patterns for the three separate non-GDDP medications versus the combined 
group of GDDP medications were less consistent; the likelihood of being in self-report only 
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or Part D only varied in direction and significance for some of the non-GDDP specific 
medications. In particular, amlodipine (combined brand name and generic) and atorvastatin 
had predicted likelihoods that were in the opposite directions for the self-report only and 
Part D only predicted likelihoods.
DISCUSSION
This study provides a relatively current assessment of the completeness of Medicare Part D 
claims based on comparisons to self-reported medication use for specific medications. The 
study analyzes several medications to assess the agreement between self-reported 
medication and Part D claims. The predicted probability and marginal effects for male 
veterans are consistent with the possibility that many veterans may fill their medications 
through the VA Pharmacy Benefit even when enrolled in Medicare Part D, resulting in 
medication reports by male veterans being less likely to be in concordance and more likely 
to be in interview self-reports only. Caution should be used, therefore, when analyzing Part 
D claims for study samples that may include veterans. Incomplete pharmacy claims may 
misclassify adherent users as non-adherent, or properly treated patients as under-treated, 
which in turn affects pharmaceutical quality measurement and improvement activities 
designed for improving medication utilization.1, 4 For veterans in particular, simultaneously 
using multiple medication measures may enhance analysis validity.8, 25
Consistent with the analysis by Roberto and Stuart,20 our results do not support that 
Medicare Part D claims were missing due to GDDP status in 2009. Instead, GDDP 
medications had a higher probability of being concordant than non-GDDP medications, with 
no statistical difference in the self-report only group. Our results provide assurance that the 
completeness and validity of Part D claims was not broadly compromised by GDDP status 
in 2009. However, we found that veteran status did account for a significantly higher 
percentage of medications that were self-report only. Roberto and Stuart’s analysis of a 
nationally representative data base found the proportion of prescriptions to be filed under 
VA coverage to be extremely small,20 so our finding of more sizeable differences in claim 
completeness by veteran status may be due to the fact that the ARIC study is conducted in 
only four geographical areas that may have utilization patterns specific to those areas. 
Alternatively, our regression-based approach controls for additional factors that may have 
enabled identification of the potential importance of veteran status for claims completeness.
The study is subject to several limitations. First, we were not able to identify specifically 
whether prescriptions were filled through GDDP plans. A study using 2007 Medicare Part D 
national sample claims showed that 80% of Part D filled prescriptions for generic 
medications from Medicare beneficiaries were available through GDDP, but only 16.3% 
were actually filled through GDDPs.13 However, the relatively high rate of claims where the 
patient payment is both relatively low and equal to the total payment is consistent with 
having a lot of Part D claims filed by GDDP pharmacies. Second, the use of GDDP plans 
has been increasing over time, so studies with more recent data may be needed to confirm 
whether the high rate of concordance for Part D claims and self-reports for GDDP drugs 
found in this study continues to hold over time. Third, our sample is not nationally 
representative. Given that prescription filing policies and mandates for different state plans 
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or large pharmaceutical chains may vary, different geographic locations or certain 
pharmacies may have substantial discrepancies.18 Fourth, the self-reports are not a gold 
standard since subjects may fail to report medications they are taking, or may report 
medications previously prescribed that they are not currently taking. Fifth, we only assessed 
a modest number of common medications for chronic conditions; though we selected drugs 
from five classes, it is possible that the trends and findings could vary in other classes of 
drugs (e.g., for medications for acute conditions, such as antibiotics). Sixth, for the time 
period studied, we did not have information on whether study participants actually filled 
prescriptions through the VA. Finally, while veteran status and the GDDP categorization 
reflect important characteristics, veteran status and GDDP status are not the only reasons 
why Part D claims may be missing; for example, we lacked information on other sources of 
pharmacy coverage or medications.
Overall, this study increases our understanding of the completeness and validity of Part D 
prescription claims. This study is important because Part D claims are increasingly being 
utilized by organizations and researchers, as well as being used as a quality measure by 
CMS. Our analysis describes the most commonly used medication utilization patterns in 
Medicare Part D claims for ARIC participants. Concordance between medication self-
reports with Medicare Part D was at least good to very good as measured by the Kappa 
statistic. We believe our study provides an important identification of the extent to which 
veteran status may be associated with missing claims in Part D; while Part D claims were 
available for many veterans, researchers may need to consider other options when using Part 
D claims for analysis of samples that include veterans. Such options might include 
controlling for veteran status, dropping veterans from the analysis, or seeking additional data 
from the Veteran’s Administration. Our study reduces concerns, however, about the extent 
to which Part D claim completeness may have been be compromised by the growth in 
generic drug plans over time for a set of frequently used chronic medications, at least 
through 2009.
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